A Single Infusion of Zoledronate in Postmenopausal Women Following Denosumab Discontinuation Results in Partial Conservation of Bone Mass Gains
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A Single Infusion of Zoledronate in Postmenopausal Women Following Denosumab Discontinuation Results in Partial Conservation of Bone Mass Gains
Authors
Keywords
-
Journal
JOURNAL OF BONE AND MINERAL RESEARCH
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2020-01-29
DOI
10.1002/jbmr.3962
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Alendronate after denosumab discontinuation in women previously exposed to bisphosphonates was not effective in preventing the risk of spontaneous multiple vertebral fractures: two case reports
- (2019) O. Lamy et al. OSTEOPOROSIS INTERNATIONAL
- Stopping Denosumab
- (2019) Olivier Lamy et al. Current Osteoporosis Reports
- Bone Loss After Romosozumab/Denosumab: Effects of Bisphosphonates
- (2018) Anne M. Horne et al. CALCIFIED TISSUE INTERNATIONAL
- Underestimation of Vertebral Fractures After Denosumab Discontinuation
- (2018) Olivier Lamy et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Effects of Long-Term Denosumab on Bone Histomorphometry and Mineralization in Women With Postmenopausal Osteoporosis
- (2018) David W Dempster et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- New and emerging concepts in the use of denosumab for the treatment of osteoporosis
- (2018) E. Michael Lewiecki Therapeutic Advances in Musculoskeletal Disease
- Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatment
- (2017) Athanasios D Anastasilakis et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension
- (2017) Steven R Cummings et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Clinical Features of 24 Patients With Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional Cases
- (2017) Athanasios D Anastasilakis et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement
- (2017) Panagiotis Anagnostis et al. MATURITAS
- Retrospective evaluation of serum CTX levels after denosumab discontinuation in patients with or without prior exposure to bisphosphonates
- (2017) B. Uebelhart et al. OSTEOPOROSIS INTERNATIONAL
- Possible protective effect of switching from denosumab to zoledronic acid on vertebral fractures
- (2017) T. Lehmann et al. OSTEOPOROSIS INTERNATIONAL
- Observations following discontinuation of long-term denosumab therapy
- (2017) M. R. McClung et al. OSTEOPOROSIS INTERNATIONAL
- 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension
- (2017) Henry G Bone et al. Lancet Diabetes & Endocrinology
- UK clinical guideline for the prevention and treatment of osteoporosis
- (2017) J. Compston et al. Archives of Osteoporosis
- AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS — 2016--EXECUTIVE SUMMARY
- (2016) Pauline M. Camacho et al. Endocrine Practice
- Severe rebound-associated vertebral fractures after denosumab discontinuation: nine clinical cases report
- (2016) Olivier Lamy et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports
- (2015) B. Aubry-Rozier et al. OSTEOPOROSIS INTERNATIONAL
- Multiple clinical vertebral fractures following denosumab discontinuation
- (2015) A. D. Anastasilakis et al. OSTEOPOROSIS INTERNATIONAL
- Discontinuation of denosumab and associated fracture incidence: Analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) Trial
- (2012) Jacques P Brown et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Effects of Denosumab Treatment and Discontinuation on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women with Low Bone Mass
- (2011) Henry G. Bone et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Effect of Denosumab on Bone Mineral Density and Biochemical Markers of Bone Turnover: Six-Year Results of a Phase 2 Clinical Trial
- (2010) Paul D. Miller et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started